Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

Overview

The primary objective is to study the effect of Denosumab on Bone Mineral Density, Standardised Uptake Value and bone metabolism in patients with total hip arthroplasty. The primary hypothesis is to demonstrate that Denosumab is superior to placebo.

Full Title of Study: “Uncemented Total Hip Implant and Subcutaneous Injections of Denosumab for Patients With Osteoarthritis of the Hip. A Randomized Double Blind Placebo Controlled Study on the Effects on Bone Evaluated With DXA, PET/CT and Biochemical Markers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: January 16, 2017

Detailed Description

A clinical study with 64 patients, age 35-65 years, with unilateral osteoarthritis of the hip, randomised to two groups of patients, either receiving Denosumab or placebo The patients will operated with an uncemented total hip arthroplasty with a Continuum acetabular cup with trabecular surface (Tantalum) and longevity Highly Cross-linked Polyethylene liner, Zimmer, Warsaw, IN, USA, and a CFP femoral stem with Titanium surface and a chrome cobalt 28 mm head, Waldemar Link, Hamburg, Germany. Clinical outcome evaluated by Harris Hip Score and EQ-5D, Bone Mineral Density by DXA, Standardised Uptake Value of Fluoride tracer, by PET/CT and biochemical markers for bone formation and bone resorption will be analyzed together with conventional radiology for implant position and fixation.

Interventions

  • Drug: denosumab
    • Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval

Arms, Groups and Cohorts

  • Active Comparator: Denosumab
    • 1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
  • Placebo Comparator: saline
    • 1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later

Clinical Trial Outcome Measures

Primary Measures

  • Bone Mineral Density
    • Time Frame: 12 months
    • Bone mineral density by DXA in Gruen Zone 7 and a sum of Gruen zone 1-7

Secondary Measures

  • Bone mineral Density
    • Time Frame: 24 months
    • BMD, g/cm2, adjacent to the femur implant for Gruen Zone 1-7, 3, 6, and 24 months after surgery
  • Standardised Uptake value
    • Time Frame: 6 months
    • fluoride isotope uptake, measured as (SUV), adjacent to the femoral stem, 3 and 6 months after surgery.
  • Standardised Uptake value
    • Time Frame: 6 months
    • fluoride isotope uptake, measured as SUV adjacent to the acetabular cup 3 and 6 months after surgery
  • Bone Mineral density
    • Time Frame: 24 months
    • BMD adjacent to the acetabular cup during the follow up period, i.e. after 3, 6, 12 and 24 months
  • Bone Mineral Density
    • Time Frame: 24 months
    • BMD at the lumbar spine and at the contra lateral nonoperated hip 6, 12 and 24 months after surgery
  • Standardised Uptake Value
    • Time Frame: 6 months
    • Fluoride isotope uptake measured as SUV at the lumbar spine and at the contra lateral nonoperated hip after 3 and 6 months
  • Biochemical markers for bone metabolism
    • Time Frame: 24 months
    • biochemical markers for bone turnover and the relation to SUV and BMD findings at the proximal femur and acetabulum during the follow up period, i.e. 3, 6, 12 and 24 months after surgery
  • Biochemical markers for bone metabolism in relation to Bone Mineral Density and Standardised Uptake Value
    • Time Frame: 24
    • biochemical markers for bone turnover and the relation to SUV and BMD findings at anatomical sites not exposed to surgery, i.e. the lumbar spine and the contra lateral hip 3 and 6 months after surgery
  • Biochemical markers for bone metabolism in relation to Bone Mineral Density and Standardised Uptake Value
    • Time Frame: 24
    • to evaluate the natural course of an uncemented THA on BMD, i.e. the placebo group 3, 6, 12 and 24 months after surgery, SUV i.e. the placebo group 3 and 6 months after surgery and on biochemical markers, i.e. the placebo group 3, 6, 12 and 24 months after surgery
  • Clinical outcome evaluation
    • Time Frame: 24 months
    • to evaluate the patients Quality of Life, measured by Harris Hip score and EQ-5D questionnaires
  • Adverse events
    • Time Frame: 24 months
    • incidence and severity of adverse events (AEs) during the study period

Participating in This Clinical Trial

Inclusion Criteria

1. male or female patient 35-65 years of age with an unilateral OAH requiring a THA and a healthy contralateral hip 2. body weight ≤110 kg or body mass index (BMI) ≤35 kg/m2 3. living in the Uppsala County 4. the eligible patients should have been given oral information, a written Patient Information and signed an Informed Consent Exclusion Criteria:

1. on or previously have had bone-specific treatment, e.g. bisphosphonates, raloxifene, parathyroid hormone, strontium ranelate, during the last five years 2. patients on systemical corticosteroid for more than 3 months should not be considered 3. patients with diagnosed malignant disease during the last five years or known to have metastasis from malignant disease should be excluded 4. patients with compromised general conditions and an American Society of Anesthesiologists, ASA-score >31 should not be regarded eligible 5. patients with known drug or alcohol abuse or regarded as socially dysfunctional, as judged by the investigator, should not be considered for the study 6. pregnant women or women planning for pregnancy or fertile women (premenopausal) without contraceptives should not be accepted for the study 7. patients that have been exposed frequently and/or have had large irradiation doses, as judged by the investigator, must not be included in the study. 8. enrolled in either another investigational drug study, in another investigational device study, or in another investigational study of an approved drug within 30 days prior to Visit 1 of the current study 9. any condition or laboratory findings which in the opinion of the Investigator makes the patient unsuitable for inclusion (for example claustrophobia)

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hans Mallmin
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Hans Mallmin, MD, PhD – Uppsala University Hospital
  • Overall Official(s)
    • Hans Mallmin, MD, PhD, Principal Investigator, Uppsala University
    • Nils Hailer, MD, PhD, Study Chair, Uppsala University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.